Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

This study provides information on the prevalence of the most important risk factors for osteoporosis and osteoporotic fracture in a large sample of women and men from the Valencia region and also provides the FRAX 10-year major and hip fracture risks for this population, as well as data about the use of diagnostic tests and antiosteoporotic treatments.

Introduction

The purpose of this study was to describe demographic characteristics, osteoporosis risk factors, the 10-year risk of osteoporotic fracture, and the use of densitometry and antiosteoporotic treatments in the Valencia region, Spain.

Methods

A cross-sectional study using the ESOSVAL cohort baseline data was conducted. We analyze the data from 5,310 women and 5,725 men aged 50 and over who attended to 272 collaborating primary care centers in 2009–2010. We collected the demographic, anthropometric, clinical, and pharmacy data from the electronic medical record.

Results

The mean age of participants was 64.3 years old for women and 65.6 years old for men. The most frequent fracture risk factors were sedentary life (22.2 %) and previous fracture (15.8 %) in women and low calcium intake (21.4 %) and current smoker (20.9 %) in men. According to FRAX®, the 10-year risk of presenting a major fracture was 5.5 % for the women and 2.8 % for the men. The 10-year risk for hip fracture was 1.9 and 1.1 % for the women and the men, respectively; 23.8 % of the women and 5.2 % of the men had a densitometry test, 27.7 % of the women and 3.5 % of the men were taking calcium and/or vitamin D supplements, and 28.2 % of the women (22.0 % in the 50–64 age group) and 2.3 % of the men were taking antiosteoporotic drugs.

Conclusions

The prevalence of certain fracture risk factors not included in the FRAX tool (sedentary life, falls, low calcium intake) is high. In young women, their low risks estimated by FRAX contrast with the high figures for densitometry testing and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sanfélix-Genovés J, Reig-Molla B, Sanfélix-Gimeno G, Peiró S, Graells-Ferrer M, Vega-Martínez M et al (2010) The population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study). Bone 47(3):610–616

    Article  PubMed  Google Scholar 

  2. Sanfélix-Genovés J, Hurtado I, Sanfélix-Gimeno G, Reig-Molla B, Peiró S (2011) Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (the FRAVO study). Health Qual Life Outcomes 6:9–20

    Google Scholar 

  3. Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14(5):383–388

    Article  PubMed  Google Scholar 

  4. Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4(6):368–381

    Article  PubMed  CAS  Google Scholar 

  5. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149(6):404–415

    PubMed  Google Scholar 

  6. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. [Available at: http://www.nof.org/]

  7. Management of osteoporosis in postmenopausal women (2010) Position statement of (2010) The North American Menopause Society. Menopause 17(1):25–54

    Article  Google Scholar 

  8. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF et al (2010) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1–37

    PubMed  Google Scholar 

  9. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254–1259

    Article  PubMed  CAS  Google Scholar 

  10. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285(6):785–795

    Article  Google Scholar 

  11. Kanis JA, on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. [Available at http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf]. Accessed 15 January 2011.

  12. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229. doi:10.1136/bmj.b4229

    Article  PubMed  Google Scholar 

  13. van den Bergh JP, van Geel TA, Lems WF, Geusens PP (2010) Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep 8(3):131–137

    Article  PubMed  Google Scholar 

  14. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD et al (2007) Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 298(20):2389–2398

    Article  PubMed  CAS  Google Scholar 

  15. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA et al (2011) FRAX(®) position development conference members. J Clin Densitom 14(3):171–180

    Article  PubMed  Google Scholar 

  16. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046

    Article  PubMed  CAS  Google Scholar 

  17. González-Macías J, Marín F, Vila J, Díez-Pérez A, Abizanda M, Alvarez R et al (2004) Risk factors for osteoporosis and osteoporotic fractures in a series of 5,195 women older than 65 years. Med Clin (Barc) 123(3):85–89

    Article  Google Scholar 

  18. Vila J, Marín F, González-Macías J, Martín D, Tojeiro S, Díez-Pérez A, representación de los investigadores del proyecto ECOSAP (2009) Validation of an algorithm to calculate the absolute risk of non-vertebral fragility fractures in a cohort of postmenopausal women. Med Clin (Barc) 133(13):501–505

    Article  Google Scholar 

  19. Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Giner V, Gil V, Pascual M et al (2010) Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. BMC Publ Health 10:153

    Article  Google Scholar 

  20. Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M et al (2011) Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain. BMC Musculoskelet Disord 12:30

    Article  PubMed  Google Scholar 

  21. Tebé C, Espallargues M, Estrada MD, Kotzeva A, del Río LM, Di Gregorio S (2011) Validación del modelo predictivo de fractura osteoporótica FRAX. Ministerio de Ciencia e Innovación. Agència d’Informació, Avaluació i Qualitat en Salut, Madrid

    Google Scholar 

  22. González-Macías J, Marin F, Vila J, Díez-Pérez A (2012) Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort. Bone 50(1):373–377

    Article  PubMed  Google Scholar 

  23. Sanfélix-Genovés J, Peiró S, Sanfélix-Gimeno G, Hurtado I, Pascual de la Torre M, Trillo-Mata JL et al (2010) Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study. BMC Health Serv Res 10:292

    Article  PubMed  Google Scholar 

  24. Sanfélix-Gimeno G, Sanfélix-Genovés J, Peiró S, Hurtado I, Trillo JL, Usó R et al (2011) Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia region (Spain). The ESOSVAL-AD study. BMC Musculoskelet Disord 12:178

    Article  PubMed  Google Scholar 

  25. Spanish Health Survey. Encuesta Nacional de Salud 2009. Available at http://www.ine.es/metodologia/t15/t1530419cues06.htm. Accessed 15 January 2012

  26. Carretero Baeza ML, Gómez Vazquez M, coord (1995) Tablas de Composición de Alimentos Españoles. Madrid: Ministerio de Sanidad y Consumo

  27. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385–397

    Article  PubMed  CAS  Google Scholar 

  28. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17):1864–1873

    PubMed  Google Scholar 

  29. Anuari Estadístic Comunitat Valenciana (2006) Valencia: Institut Valencià d’Estadística; 2007

  30. Arana-Arri E, Gutiérrez-Ibarluzea I, Ecenarro Mugaguren A, Asua Batarrita J (2007) Prevalence of certain osteoporosis-determining habits among post menopausal women in the Basque Country, Spain, in 2003. Rev Esp Salud Publica 81(6):647–656

    Article  PubMed  Google Scholar 

  31. Luz Rentero M, Carbonell C, Casillas M, González Béjar M, Berenguer R (2008) Risk factors for osteoporosis and fractures in postmenopausal women between 50 and 65 years of age in a primary care setting in Spain: a questionnaire. Open Rheumatol J 2:58–63

    Article  PubMed  Google Scholar 

  32. Roig Vilaseca D, Gómez Vaquero C, Hoces Otero C, Nolla JM (2010) Fracture risk calculated with the FRAX index in patients with osteoporosis treated and untreated. Med Clin (Barc) 134(5):189–193

    Article  Google Scholar 

  33. Azagra Ledesma R, Prieto-Alhambra D, Encabo Duró G, Casado Burgos E, Aguyé Batista A, Díez-Pérez A, grupo de estudio FRIDEX (2011) Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population. Med Clin (Barc) 136(14):613–619

    Article  Google Scholar 

  34. Del Río BL, Tebé Cordomi C, Johansson H, Di Gregorio MS, Estrada Sabadell D, Espallargues Carreras M (2011) Evaluación del riesgo absoluto de fractura mediante herramienta FRAX® en una cohorte española. Rev Osteoporos Metab Miner 3(2):85–93

    Google Scholar 

  35. Tebé C, del Río LM, Casas L, Estrada MD, Kotzeva A, Di Gregorio S, Espallargues M (2011) Risk factors for fragility fractures in a cohort of Spanish women. Gac Sanit 25(6):507–512

    Article  PubMed  Google Scholar 

  36. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010) Clinical characteristics of patients under treatment for osteoporosis in a primary care centre. Who do we treat? Aten Primaria 42(11):559–563

    Article  PubMed  Google Scholar 

  37. Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78–85

    Article  PubMed  CAS  Google Scholar 

  38. Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12(7):519–528

    Article  PubMed  CAS  Google Scholar 

  39. McGrother CW, Donaldson MM, Clayton D, Abrams KR, Clarke M (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton osteoporotic fracture (MOF) study. Osteoporos Int 13(1):89–96

    Article  PubMed  CAS  Google Scholar 

  40. Warensjö E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A et al (2011) Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 342:d1473

    Article  PubMed  Google Scholar 

  41. Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA et al (2011) Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int 22(3):817–827

    Article  PubMed  CAS  Google Scholar 

  42. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis J et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25(11):2350–2358

    Article  PubMed  Google Scholar 

  43. Couris CM, Chapurlat RD, Kanis JA, Johansson H, Burlet N, Delmas PD et al (2011) FRAX(®) probabilities and risk of major osteoporotic fracture in France. Osteoporos Int. doi:10.1007/s00198-011-1883-8

  44. Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC et al (2010) Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 25(7):1506–1511

    Article  PubMed  Google Scholar 

  45. Trémollieres F, Cochet T, Cohade C, Pouillès JM, Ribot C (2010) Fracture risk in early postmenopausal women assessed using FRAX. Joint Bone Spine 77(4):345–348

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to all the doctors and nurses in the Valencia Health Agency primary health-care centers participating in the ESOSVAL study for their collaboration and to the Valencia Department of Health for its enthusiastic and continuous support of the ESOSVAL research projects.

Conflicts of interest

None of the sponsors played any role in the design of the ESOSVAL studies; the collection, analysis or interpretation of data; the writing of the manuscripts; or in the decision to submit it for publication. JSG and SP have received research grants from various pharmaceutical companies and from fees for participating in scientific meetings sponsored by pharmaceutical companies.

Author information

Authors and Affiliations

  1. Health Services Research Unit, Centro Superior de Investigación en Salud Pública (CSISP), Avda. de Cataluña 21, 46020, Valencia, Spain

    J. Sanfélix-Genovés, G. Sanfélix-Gimeno, S. Peiró, I. Hurtado & C. Baixauli

  2. Fundación de Investigación del Hospital Clínico Universitario–Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain

    J. Sanfélix-Genovés & C. Fluixà

  3. Centro de Salud de Alginet, Departamento La Ribera, Agencia Valenciana de Salud, Valencia, Spain

    A. Fuertes

  4. Centro de Salud de Villamarxant, Departamento Valencia-Arnau de Vilanova-Liria, Agencia Valenciana de Salud, Valencia, Spain

    J. C. Campos

  5. Centro de Salud de Ciudad Jardin, Departamento Alacant-Hospital General, Agencia Valenciana de Salud, Valencia, Spain

    V. Giner

Authors
  1. J. Sanfélix-Genovés
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Sanfélix-Gimeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Peiró
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Hurtado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Fluixà
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Fuertes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. C. Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Giner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Baixauli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Sanfélix-Genovés.

Appendix

Appendix

Table 5 Age and sex distribution in the general population of the Valencia region, the ESOSVAL cohort, and weights used for weighting totals
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanfélix-Genovés, J., Sanfélix-Gimeno, G., Peiró, S. et al. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int 24, 1045–1055 (2013). https://doi.org/10.1007/s00198-012-2018-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-012-2018-6

Keywords

Search

Navigation